Lentiviral overexpression of VEGFC in transplanted MSCs leads to resolution of swelling in a mouse tail lymphedema model
Abstract
Dysfunction of the lymphatic system following injury, disease, or cancer treatment can lead to lymphedema, a debilitating condition with no cure. Despite the various physical therapy and surgical options available, most treatments are palliative and fail to address the underlying lymphatic vascular insufficiency driving lymphedema progression. Stem cell therapy provides a promising alternative in the treatment of various chronic diseases with a wide range of therapeutic effects that reduce inflammation, fibrosis, and oxidative stress, while promoting lymphatic vessel (LV) regeneration. Specifically, stem cell transplantation is suggested to promote LV restoration, rebuild lymphatic circulation, and thus potentially be utilized towards an effective lymphedema treatment. In addition to stem cells, studies have proposed the administration of vascular endothelial growth factor C (VEGFC) to promote lymphangiogenesis and decrease swelling in lymphedema.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 23, 2022
- Source ID
- 10.1111/micc.12792
Entities
People
- Eleftheria Michalaki
- J Brandon Dixon
- Josephine M. Rudd
- Lauren Liebman
- Levi B. Wood
- Nick J. Willett
- Rahul Wadhwani
Organizations
- American Heart Association
- Georgia Tech
- National Center for Advancing Translational Sciences
- United States Department of Defense
- University of Oregon